What Сиднофарм treats: Main Uses and Benefits

Molsidomine is commonly used as a long-term, routine therapy for stable angina pectoris, a condition characterized by recurrent chest discomfort due to reduced blood flow to the heart muscle. The drug is primarily classified as a vasodilator used in angina. The medication is applied across domains where additional symptomatic support is needed, addressing symptom clusters that may become disruptive.

The primary therapeutic benefit may be a reduction in the frequency and intensity of anginal attacks. It is considered relevant for managing ischemic heart disease, chronic stable angina, and as adjunctive support for Chronic Congestive Heart Failure (conditions marked by increased physiological stress). This support helps patients cope more steadily with chronic episodes and contributes to improved day-to-day comfort.

“This therapy assists in easing the overall symptom load and may help lessen the degree to which routine activities are restricted by anginal pain.”

---

Quick Fact: Relevant for Ischemia-Related Chest Discomfort

Property	Description
Primary Indication	Chronic Stable Angina Pectoris
Key Symptom Target	Recurrent chest pain, reduced exercise tolerance
Main Benefit	May assist in reducing symptom frequency and intensity

Regulatory References

1. NIH's Medical Subject Headings (MeSH)

Eligibility for Molsidomine

The eligibility profile for Molsidomine (Сиднофарм) is defined by official regulatory documents based on acute hemodynamic status and existing patient comorbidities. Use is strictly reserved for adults (aged 18 years and older) with stable cardiac conditions.

Category	Official Regulatory Status
Absolute Contraindications	Prohibited for patients with severe hypotension (e.g., systolic BP below 100 mmHg), acute circulatory failure, cardiogenic shock, or known hypersensitivity to the drug.
Drug Contraindication	Strictly prohibited with Phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) and other Nitric Oxide donors.
Special Populations	Contraindicated during lactation (breastfeeding). Use is not established and not recommended in the pediatric population (lt 18 years).
Conditional Use	Patients with significant hepatic impairment or severe renal impairment may require conditional use and close regulatory monitoring due to altered drug clearance.

These official statements define the absolute boundaries of who may use the medicine and who must not, based on the documented risks of its vasodilatory effects and metabolic constraints.

The interaction profile for Molsidomine is defined by several officially documented constraints and pharmacodynamic effects. A formal regulatory prohibition exists against the co-administration of Molsidomine with Phosphodiesterase type 5 (PDE5) inhibitors, including Sildenafil, Tadalafil, and Vardenafil. This strict restriction is explicitly stated in prescribing information due to the significant and sudden risk of severe hypotension.

The medication also exhibits pronounced additive pharmacodynamic effects. Its blood pressure-lowering action is officially enhanced when combined with other antihypertensive agents, such as beta-blockers, ACE inhibitors, or calcium channel blockers, and with other vasodilators like organic nitrates. Furthermore, the consumption of alcohol is officially documented to potentiate the hypotensive effect of Molsidomine.

Regarding pharmacokinetics, regulatory documents note specific population-dependent constraints. The clearance of Molsidomine is officially documented to be impaired in patients with hepatic impairment (liver disease), which results in an increased systemic exposure ( AUC) of the drug and its active metabolite. Similarly, individuals of advanced age are observed to have a prolonged half-life and increased systemic exposure. These conditions are officially recognized as altering the drug's disposition in the body.

The action of Сиднофарм begins as the prodrug Molsidomine is converted into its active metabolite, Linsidomine ( SIN-1). This intermediate spontaneously decomposes in an oxygen-dependent, non-enzymatic reaction to directly liberate Nitric Oxide ( NO), the key signaling molecule. This unique release mechanism avoids the enzyme-dependent system used by some other vasodilators, a factor that contributes to a more consistent functional response by avoiding the tolerance seen with other pathway modulators.

The released NO diffuses to vascular smooth muscle cells and activates the enzyme soluble Guanylate Cyclase ( sGC). This leads to a substantial increase in cyclic Guanosine Monophosphate ( cGMP), which ultimately reduces intracellular calcium and results in vasodilation (widening of the blood vessels).

This resulting vasodilation is observed in both venous (capacitance) and arterial (resistance) vessels. This system-level effect results in a reduction of the blood volume returning to the heart (preload) and a lowering of the pressure against which the heart must pump (afterload). This dual reduction constitutes the final mechanistic sequence, resulting in a lessened mechanical workload of the cardiac muscle and a corresponding decrease in oxygen demand.

How Сиднофарм is Used: Official Administration Guidelines

Сиднофарм (Molsidomine) is officially administered via two primary routes: oral (tablet form) for long-term management, and intravenous (IV) for acute, supervised care settings.

Labeled Dosing Regimens (Adults)

Regimen Type	Typical Dose Range	Maximum Daily Dose
Oral (Immediate-Release)	2 mg to 4 mg per administration	Typically up to 12 mg
Intravenous (IV)	2 mg to 4 mg per dose	Up to 40 mg

For chronic oral use, the immediate-release tablets are generally scheduled for multiple daily doses (two to four times per day) to ensure consistent therapeutic concentrations. The prolonged-release formulations, where available, are typically scheduled for once or twice daily use. Oral tablets should be swallowed whole and can be taken with or without food.

The intravenous formulation, reserved for acute administration in a supervised environment, may be infused at a controlled rate not to exceed 3 mg per hour. This difference in administration type reflects the drug’s dual role in both chronic and acute cardiovascular support.

Population-Specific Administration Rules

Official labeling requires specific dose adjustments for certain populations. A lower starting dose is generally recommended for older adults and patients with hepatic impairment due to potential changes in drug clearance. Furthermore, the medicine is not recommended for administration to children or the pediatric population.

Research evidence / Overview of studies for Сиднофарм (Molsidomine)

Evidence for Use in Chronic Stable Angina

Research examined Сиднофарм (Molsidomine) in the context of chronic stable angina, conducted primarily through short-term, randomized controlled trials (RCTs). These studies typically use double-blind designs and often use comparative studies. The main focus of this research was to monitor symptomatic outcomes related to physical discomfort.

Studies monitored patient-reported experiences, such as the frequency of anginal episodes and the recorded use of short-acting sublingual nitrates over defined time intervals. Research also examined physical functioning by assessing exercise capacity. Findings describe patterns observed in the studies related to the measured frequency of anginal attacks and nitrate use over the short study periods.

However, the research highlights areas of uncertainty. While short-term findings are available, there is limited information for long-term outcomes that may provide clarity regarding patterns related to major cardiovascular outcomes (such as severe events or survival). Some studies exploring specific vascular biomarkers have described mixed findings for all pre-specified outcomes, with data showing variability in this area.

---

Research on Adjunctive Use in Chronic Heart Failure

The evidence base related to research scenarios for chronic congestive heart failure primarily comes from older, smaller clinical trials focusing on temporary physiological imbalance. These studies were used to evaluate its effect on systemic or functional imbalance by monitoring hemodynamic parameters.

Researchers studied patients with conditions marked by functional limitations and measured outcomes related to physiological strain. Specifically, studies monitored changes in pressures within the heart, such as the left ventricular filling pressure and pulmonary artery pressure. Studies monitored measured changes in these specific pressures. Findings indicate that the highest recorded changes were observed shortly after administration. Research describes measured shifts in the patients' functional class, which is a patient-reported outcome describing perceived discomfort and daily functioning.

---

What Remains Uncertain and Current Research Gaps

One of the primary research limitation frames is the general lack of large-scale RCTs focusing on hard, long-term cardiovascular outcomes (such as reducing the risk of a heart attack or the need for re-hospitalization). The existing evidence for efficacy is predominantly based on functional measures and surrogate endpoints (like exercise time and symptom frequency). Comparative evidence is lacking for certain research scenarios, and for research scenarios for chronic heart failure, the core research base is older. Research does not determine whether an individual will respond similarly across all these metrics, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Molsidomine - NIH Medical Subject Headings (MeSH) for Prodrug Classification

Common questions about Сиднофарм (FAQ)

Q: Is Сиднофарм generally considered appropriate for long-term use?

Official information indicates that this medicine is classified as a long-acting agent intended for the long-term management of stable heart conditions. The overall duration of treatment is officially determined based on the patient's specific medical condition and how they respond to the medicine. The drug is intended to provide a sustained therapeutic effect, and some formulations are developed to cover a full 24-hour period.

Q: Can people with liver or kidney problems use Сиднофарм?

Regulatory documents state that the medicine is primarily processed by the liver. Because of this, clearance is officially documented as impaired in individuals with hepatic (liver) impairment. Regulatory information notes that a lower starting dose is generally recommended for patients with hepatic impairment. While clearance is not significantly altered by impaired renal (kidney) function, individuals with kidney impairment may still experience altered elimination of the drug and its active form.

Q: Does the body become dependent on Сиднофарм over time, according to research?

Studies and official information indicate that the medicine's unique mechanism of action avoids the enzyme-dependent system used by some other vasodilators (medicines that widen blood vessels). This non-enzymatic action is described as helping to maintain a functional response by avoiding the tolerance that can be seen with some other pathway-modifying drugs.

Q: Is Сиднофарм similar to a beta-blocker?

No. Сиднофарм is officially classified as a systemic vasodilator and antianginal agent, meaning it works by directly relaxing and widening blood vessels. Its blood pressure-lowering action is officially described as additive (meaning it enhances the effect) when combined with other antihypertensive agents, such as beta-blockers, confirming they belong to different classes of medication.

Q: How quickly does Сиднофарм typically start working after being taken?

According to official regulatory data, peak concentrations of Molsidomine and its active form are typically reached in the blood plasma 1 to 2 hours after the tablet is taken by mouth.

Q: Are there different strengths of Сиднофарм tablets available?

Official documents refer to immediate-release formulations with dose ranges from 2 mg to 4 mg. Clinical studies also describe prolonged-release formulations in dose ranges such as 8 mg and 16 mg.

Q: What is the typical duration of effect for a single dose of Сиднофарм?

Regulatory-consistent information indicates that the duration of the medicine’s action is longer than its elimination half-life (the time it takes for the body to clear half the drug). Studies monitoring physical functioning have observed a reduction in a key measured effect lasting for up to six hours after a dose is taken.

Q: Are there any restrictions on driving or operating machinery while using Сиднофарм?

Because Сиднофарм is known to commonly cause adverse reactions such as dizziness and headache, official labels generally advise caution when side effects that may affect these functions are present.

Q: How long is a typical course of treatment with Сиднофарм?

The medicine is classified for use in the long-term management of stable cardiac conditions rather than as a short-term intervention. The duration of treatment is not fixed but is officially based on the individual patient’s medical condition and their established response to the medication.

The storage and disposal of Сиднофарм (Molsidomine tablets) must comply strictly with official regulatory guidelines to maintain product quality.

Required Storage and Protection

The product must be stored at a temperature not exceeding 30 C and must not be frozen. It is mandatory to store the medicine in its original package, with the container kept tightly closed, to protect the tablets from moisture and light. The product is not intended for use after the expiration date printed on the package.

Child Safety and Disposal Rules

All pharmaceutical product labeling requires that Сиднофарм be kept out of the sight and reach of children. Any unused or expired medicine must be handled and disposed of in accordance with local requirements. Official guidance generally instructs against discarding medications via household waste or flushing them down the toilet or sink.